Cutaneous Oncology in the Immunosuppressed

Wang, Leo; Lin, Stephanie K.; Stull, Carolyn; Shin, Thuzar M.; Higgins, H. William; Giordano, Cerrene N.; McMurray, Stacy L.; Etzkorn, Jeremy R.; Miller, Christopher J.; Walker, J.

doi:10.1016/j.det.2022.07.012

Cited by 4 publications

(4 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several types of immunotherapy: (1) drug-based blockage of inhibitory pathways with immune checkpoint inhibitors, (2) antibody treatment to trigger a natural immune response, and (3) CAR-T cell therapy. The first two categories have received much attention and advancement in the last few decades with the clinical success of regimes against CTLA4 and PD-1/PDL-1 across various cancers [121]. Zelin et al (2022) [119] reported on the reported efficacies of immune checkpoint inhibitor regimes for basal, squamous, and Merkel cell carcinomas using the RECIST framework and careful consideration of how patient profiles factor into therapy success (Table 4).…”

Section: Antiviral Medicationsmentioning

confidence: 99%

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

Ebrahimnejad,

Jaafar,

Goodarzi

2024

Physiologia

View full text Add to dashboard Cite

When thinking of skin disease, cancer comes up almost immediately as an example. While the American Cancer Society lists 6 major cancer types, the National Institute of Arthritis and Musculoskeletal and Skin Diseases identifies 13 significant benign skin disorders, reflecting the diversity of skin conditions in dermatology. This topical review aims to provide an overview of the pathophysiology of these major skin cancers and disorders and to summarize conventional diagnostic methods and current treatment approaches.

show abstract

Section: Antiviral Medicationsmentioning

confidence: 99%

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

Ebrahimnejad,

Jaafar,

Goodarzi

2024

Physiologia

View full text Add to dashboard Cite

show abstract

“…Immunosuppressed patients such as solid-organ transplant recipients, patients with HIV, and those with hematologic malignancies are at a higher risk of developing MCC, hence their inclusion is vital. 19,20 Patient demographics seen in real-world studies are described in Table 1. 3,9,[11][12][13][21][22][23] Although MCC is reported to occur predominantly on the head and neck, an analysis of 54 advanced MCC patients conducted in the Netherlands, indicated that tumors occurred on the trunk, head and neck, and extremities 15%, 24%, and 46% of the time, respectively.…”

Section: Demographicsmentioning

confidence: 99%

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival

Lohray,

Verma,

Wang

et al. 2023

POR

View full text Add to dashboard Cite

Introduction:Avelumab is a programmed cell death-ligand 1 (PD-L1) inhibitor approved by the Food and Drug Administration for advanced Merkel cell carcinoma (MCC). Studies conducted in real-world settings have shed light on its effectiveness and safety in clinical settings. Areas Covered: Real-world studies on avelumab for MCC from North and South America, Europe, and Asia have been presented in this review. Most studies are on patients over age 70 and have a male-predominant sex ratio. Overall response rates range from 29.1% to 72.1%, (disease control rate: 60.0-72.7%; complete response rate: 15.8%-37.2%; partial rate: 18.2-42.1%; stable disease: 7.1-30.9%; progressive disease: 7.1-40.0%) and median progression free survival ranges from 8.1 to 24.1 months depending on the population studied. Immunosuppressed patients appear to benefit from avelumab as well, with response rates equivalent to the general population. Patients receiving avelumab as a first-line agent tend to have better outcomes than those using it as a second-line therapy. Fatigue, infusion-related reactions, and dyspnea were some of the most common adverse events identified in real-world studies. Autoimmune hepatitis and thyroiditis were also observed. Conclusion:The use of avelumab as a safe and effective treatment option for advanced MCC is supported by real-world data, although additional study is required to assess long-term efficacy and safety outcomes.

show abstract

“…They also offer an alternative to using corticosteroids which are used as first-line treatment for autoimmune cases such as pemphigus [118]. Some diseases have treatments that avoid corticosteroids all together such as kaposi sarcoma [119].…”

Section: Antiviral Medicationsmentioning

confidence: 99%

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

Ebrahimnejad,

Goodarzi

2023

Preprint

View full text Add to dashboard Cite

When the skin is afflicted by disease such as cancer, these essential functions are disrupted, putting the entire person at risk. While the American Cancer Society lists 6 major cancer types, the National Institute of Arthritis and Musculoskeletal and Skin Diseases identifies 13 significant benign skin disorders, reflecting the diversity of skin conditions in dermatology. This topical review aims to provide an overview of the pathophysiology of these major skin cancers and disorders and summarize conventional diagnostic methods and current treatment approaches.

show abstract

Cutaneous Oncology in the Immunosuppressed

Cited by 4 publications

References 68 publications

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival

The Past, Present, Future: Pathophysiology, Diagnosis, and Treatment of Human Skin Diseases

Contact Info

Product

Resources

About